Review of infective dose, routes of transmission, and outcome of COVID-19 caused by the SARS-COV2 virus: comparison with other respiratory viruses

Running title: COVID-19 infective dose review

Sedighe Karimzadeh ¹, Raj Bhopal ²*, Nguyen Tien Huy ³*

Affiliation

¹School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
²Usher Institute, University of Edinburgh, Edinburgh EH3 9AG, UK
³School of Tropical Medicine and Global Health, Nagasaki University, Japan

*Correspondence to Nguyen Tien Huy, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan. (E-Mail: tienhuy@nagasaki-u.ac.jp) or Raj Bhopal, Usher Institute, University of Edinburgh, Edinburgh EH3 9AG, UK (E-Mail: Raj.Bhopal@ed.ac.uk)

Authors email:

SK: sediqekarimzadeh@gmail.com
RB: Raj.Bhopal@ed.ac.uk
NTH: tienhuy@nagasaki-u.ac.jp
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. Prevention and control strategies require an improved understanding of SARS-CoV-2 dynamics. We did a rapid review of the literature on SARS-CoV-2 viral dynamics with a focus on infective dose. We sought comparisons of SARS-CoV-2 with other respiratory viruses including SARS-CoV-1 and MERS-CoV. We examined laboratory animal, and human studies. The literature on infective dose, transmission, and routes of exposure was limited specially in humans, and varying endpoints were used for measurement of infection. We propose the minimum infective dose of COVID-19 in humans, is higher than 100 particles, possibly slightly lower than the 700 particles estimated for H1N1 influenza. Despite variability in animal studies, there was some evidence that increased dose at exposure correlated with higher viral load clinically, and severer symptoms. Higher viral load measures did not reflect COVID-19 severity. Aerosol transmission seemed to raise the risk of more severe respiratory complications in animals. An accurate quantitative estimate of the infective dose of SARS-CoV-2 in humans is not currently feasible and needs further research. Further work is also required on the relationship between routes of transmission, infective dose, co-infection, and outcomes.

Keywords: infective dose, SARS-CoV-2, COVID-19, respiratory viruses, viral load, viral dynamics
Abbreviation:

BALB/c: begg albino laboratory-bred
C57BL/6: c57 black strain 6
COVID-19: coronavirus disease 2019
CPE: cytopathogenic effect
hACE2: human angiotensin converting enzyme 2
ID_{50}: median infectious dose
MERS: middle east respiratory syndrome
PFU: plaque forming unit
RSV: respiratory syncytial virus
SARS: severe acute respiratory syndrome
TCID_{50}: median tissue culture infective dose
tgMice: transgenic mice
1. Introduction

COVID-19 is a severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) which is now pandemic. Several fundamental virologic concepts relating to COVID-19 remain poorly understood such as the initiating event and infective dose i.e. number of particles to cause a detectable infection. It is unclear whether the number of particles on exposure is correlated with the severity and outcome of disease. Understanding of these concepts requires experimental studies to complement epidemiologic data that can only provide limited insights into these matters. Improved understanding of viral concepts of COVID-19 can promote more effective outbreak control strategies. We did a rapid review of the evidence for the infectious dose, viral load, co-infection, route of transmission, and correlation with the outcome of SARS-CoV-2 infection. To help interpret the limited data available we compared viral dynamics of SARS-CoV-2 with other respiratory pathogens such as influenza virus, SARS-CoV-1 and MERS-CoV viruses.

2. Methods

We identified relevant data for this review by searching databases including PubMed and Google Scholar, using the terms “Infective dose”, “Respiratory viruses”, “SARS-CoV”, “MERS-CoV”, “Aerosol”, “COVID-19”, “viral load”, “Coronavirus”, “Influenza virus”. The latest literature search was performed on Sep 1, 2020 with no restriction on date of publication and study design. We included articles published in English with full-text version available. We did not limit our search to peer-reviewed journals.

3. Result

We included 79 experimental and human studies exploring the infective dose, viral load, route of administration, exposure, and outcome in respiratory viruses. We extracted data for respiratory viruses including coronaviruses (Seasonal CoV, SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza virus, rhinovirus, coxsackievirus, adenovirus and respiratory syncytial virus (RSV).
3.1. Infective dose

For comprehension of viral pathogenicity, determining the number of particles that trigger infection is crucial. A low infectious dose could mean the organism is highly transmissible person-to-person and via touching contaminated surfaces [1]. The main methods for defining the infective viral dose is through studies utilizing dilution of virus studies for cytopathogenic effect (CPE) in 50% of inoculated culture cells (known as tissue culture infectious dose, or TCID₅₀), or by counting plaque-forming units; each plaque in a layer of host cells indicating colonization by a single virus particle (PFU) [2]. TCID₅₀ is the viral dose that induces either pathological changes or cell death in 50% of inoculated cultures. The viral plaque assay is a quantitative measure of the number of particles that form a plaque, estimating viral concentration in plaque-forming units [3]. A virus titer of 0.7 PFU can be estimated as theoretically equivalent to 1 TCID₅₀, so given that most studies reported the latter we converted the results for those reporting PFU [3]. For determining the infectious dose (ID₅₀) in humans the viral administration should, ideally, be in controlled experiments. Since patient safety concerns would usually make this unethical, animal-based experimental studies are mostly used for simulating infection in humans [4]. We have summarized in tables 1 and 2 the infectious dose reported for some major human respiratory viruses identified by either experimental infection in human volunteers or laboratory animals.

3.2. Human studies on infective dose of COVID-19 and other relevant viruses

Irrespective of the route of inoculation, some respiratory viruses such as rhinoviruses and adenoviruses mostly cause asymptomatic or mild respiratory symptoms in immunocompetent hosts. Although the minimum infective dose causing COVID-19 in humans is unknown it is assumed to be low since the virus transmits rapidly. The route of inoculation affects the response to viruses [4]. Infective dose assessment in human studies requires intranasal administration of the virus via drops or aerosols. Infection with drops informs us about upper respiratory tract infection, while aerosols can inform about lower respiratory tract infection [4].

We found no experimental studies of this kind in humans but one observational study. Isolation of SARS-CoV-2 from oropharyngeal and nasopharyngeal sample of one patient in the USA and inoculation in Vero cells shows that SARS-CoV-2 can replicate rapidly and achieve 10⁵ TCID₅₀/mL within 24-hour post-infection [5] (Study not tabulated). Although virus titer peaked at >10⁶ TCID₅₀/mL after 48 hour post-inoculation, major CPE (cytopathogenic effect) was
observed after 60 hours post-inoculation [5]. This infective dose is much higher than rhinovirus but lower than for influenza virus and similar to coxsackievirus when administered nasally.

Table 1 shows human studies in healthy volunteers on other relevant respiratory viruses.

a) Coronavirus

The human ID$_{50}$ for seasonal coronavirus subtype 229E that causes mild common cold in humans was reported to be 13 TCID$_{50}$ [6].

b) Influenza

The infective dose for H1N1 strain of influenza virus by nasal drop was $10^3$ TCID$_{50}$ (Table 1, B) [7]. For the H2N2 strain by aerosol administration that TCID$_{50}$ was 0.6-3.0 TCID$_{50}$ [8], higher than by intranasal drop (127–320 TCID$_{50}$) [9]. For the H3N2 strain by nasal drop was $1\times10^7$ TCID$_{50}$ [10].

c) Rhinovirus

The TCID$_{50}$ of rhinovirus when administered by aerosols at 0.68 TCID$_{50}$ was about 20 times greater than by nasal drops (0.032 TCID$_{50}$) [11].

d) Adenovirus

For Adenovirus type 4 the TCID$_{50}$ was 35 TCID$_{50}$ by intranasal route and 0.5 TCID$_{50}$ by aerosol [12]. In this study 6.6 particles by aerosol (corresponding to 462 particles by nasal drop) were required to initiate infection in 50% of the population. Furthermore, a high dose of virus by nasal drops was found to cause infection in the lower intestinal tract [12].

e) Coxsackievirus

TCID$_{50}$ of coxsackievirus A21 strain was 6 TCID$_{50}$ when administered by intranasal droplet compared with 28-34 TCID$_{50}$ by aerosol [11].

f) Respiratory syncytial virus (RSV)

Attenuated vaccine strain of RSV, TS-1, at a dose of 30-40 TCID$_{50}$ infected infants. This infectious dose of RSV is assumed to be lower than with the wild strain because of its lesser virulence through multiple passages in tissue culture [13]. Type-39 had a TCID$_{50}$ of 100 [14].
3.3. Animal Studies

3.3.1 SARS-CoV-2

Table 2 summarizes experimental animal studies on SARS-CoV-2.

a) Ferret

Intranasal inoculation of $10^{5.5}$ TCID$_{50}$ (221,359 PFU) of SARS-CoV-2 virus presented raised body temperature and decreased activity in ferrets [15]. One out of six ferrets that were infected by intranasal route at a dose of 500 PFU showed signs of upper respiratory tract viral replication. Meanwhile, all ferrets presented with pulmonary histopathological features and viral RNA replication at higher doses (50,000-5,000,000 PFU) [16, 17].

b) Mice

An study on hACE2 transgenic mice after intranasal inoculation at a dose of $10^5$ TCID$_{50}$ (70,000 PFU) of SARS-CoV-2 showed weight loss and viral replication in the lungs [18]. Another study on both young and aged hACE2 mice after infection at a dose of 400,000 PFU ($\approx 5.71 \times 10^5$ TCID$_{50}$) by intranasal route showed mild weight loss (10%) and more severe histopathological features of interstitial pneumonia in aged mice [19]. Mice infected by the intragastric route at a dose of 4,000,000 PFU ($\approx 5.71 \times 10^6$ TCID$_{50}$) showed pulmonary infection in one of three mice [19]. Transgenic mice after aerosol inoculation of SARS-CoV-2 isolates at a dose of 630 PFU showed viral RNA, interstitial pneumonia, and pulmonary infiltration after at least 25 min exposure to the virus [20]. After intranasal infection with 21000 PFU of SARS-CoV-2, three out of six hACE2 mice died at 6 days post infection [21]. Similarly 40% mortality in BALB/c mice was observed after intranasal infection with SARS-CoV-2 at a dose of 100,000 PFU [22]. BALB/c mice showed viral replication and interstitial pneumonia at a dose of 16,000 PFU by the intranasal route [23].

c) Cynomolgus macaques

After aerosol inoculation at a dose of 48,600 PFU macaques presented modest clinical signs, viral RNA, and pulmonary pathological features [24]. After inoculation at a dose of 700,000 PFU ($10^6$ TCID$_{50}$) of SARS-CoV-2 intranasally and intrathecally, cynomolgus macaques presented no clinical signs, however, histopathological changes indicating diffuse alveolar damage and viral replication were observed [25].
d) Rhesus macaques

Rhesus macaques infected with SARS-CoV-2 at a dose of 700,000 PFU ($10^6$ TCID$_{50}$) via ocular conjunctivae presented mild pneumonia and higher viral RNA than those infected intrathecally, whereas no viral RNA was detected after exposure by the intragastric route [26]. After inoculation at a dose of 2,600,000 TCID$_{50}$ (1,820,000 PFU) of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes, macaques showed various range of clinical signs including weight loss, piloerection, decreased appetite, pallor and dehydration [27]. Exposure to higher doses and correlation with signs of infection such as decrease in appetite and response to stimuli as well as slight neutropenia and lymphopenia was observed in a group of rhesus macaques that were infected at a dose of 1,100,000 PFU ($\approx 1.57 \times 10^6$ TCID$_{50}$). Two groups of rhesus macaques that were infected by intranasal and intrathecal route at a dose of 110,000 PFU ($\approx 1.57 \times 10^5$ TCID$_{50}$) and 110,000 PFU ($\approx 1.57 \times 10^4$ TCID$_{50}$) presented mild clinical disease. Histopathological features of pneumonia were observed at a dose of 110,000 PFU [28]. Rhesus macaques exposed by aerosol route at a dose of 28700 PFU showed mild clinical signs of pulmonary infection [24].

e) African green monkey

All three African green monkeys exposed to 36000 PFU by the aerosol route showed clinical signs of pulmonary disease [24]. African green monkeys inoculated by combined intranasal and intrathecal routes at a dose of 500,000 PFU ($\approx 7.14 \times 10^5$ TCID$_{50}$) showed histopathological features of pulmonary lesions and no overt clinical signs of disease [29]. At a dose of 3,000,000 PFU ($\approx 4.28 \times 10^6$ TCID$_{50}$) they showed efficient viral replication and respiratory signs of infection [30]. Two African green monkeys exposed at a dose of 2000 PFU by the aerosol route and 3,610,000 PFU by combined route of intranasal, thecal, ocular and oral showed signs of acute respiratory distress syndrome (ARDS), increased level of interleukin 6 (IL6) and cytokine storm [31].

f) Hamsters

In two groups of juvenile and adult hamsters infected by intranasal and ocular routes with SARS-CoV-2 at a higher and lower dose of $10^{5.6}$ PFU ($\approx 5.68\times 10^5$ TCID$_{50}$) and 1000 PFU ($\approx 1.42\times 10^3$ TCID$_{50}$), respectively, higher dose infected hamsters presented more severe lung complications, earlier weight loss, and earlier pneumomediastinum than the lower dose group [32]. Hamsters that
were intranasally inoculated at a dose of 56000 PFU showed weight loss and viral shedding [33]. After intranasal infection at a dose of 100,000 PFU hamsters showed both clinical presentation and viral RNA [34]. Immunosuppressed hamsters after intranasal inoculation at doses of 100, and 1000 PFU showed extreme weight loss whereas death was observed in those exposed to 10,000 PFU [35].

g) Bats and other animals

Intranasal inoculation of $10^5$ TCID$_{50}$ (70,000 PFU) of SARS-CoV-2 isolates into fruit bats, pigs, chickens, cats, dogs (data not tabulated for the latter four species) showed no clinical signs and viral RNA replication in except slight viral RNA and shedding in cats and bats [36, 37].

3.3.2 Other Coronaviruses

We examined findings on other coronaviruses, including Seasonal CoV, SARS-CoV-1 and MERS-CoV for relevant insights. Two group of BALB/c mice and C57BL/6 mice after infection with HCoV-OC43 at a dose of $10^5$ TCID$_{50}$ (70,000 PFU) by intraperitoneal and intracerebral route showed 100% lethality at 8 days [38]. However, at a dose of $10^4$-$10^5$ TCID$_{50}$ (7000-70,000 PFU) they presented no clinical signs and viral RNA by intraoral route and mild signs of infection by intranasal route at 21 days postnatal [38]. In another study twelve days old BALB/c mice exposed by the intracerebral route at a dose of 100 TCID$_{50}$ (70 PFU) of wild type HCoV-OC43 showed 100% lethality 4 days later [39]. Estimated infectivity of SARS-CoV-1 was comparable to other coronaviruses including HCoV-229E a causative agent for a mild cold in humans. ID$_{10}$ and ID$_{50}$ of SARS-CoV-1 were reported as 43 and 280 PFU (400 TCID$_{50}$) in an experimental study [6]. A study on transgenic mice reported the ID$_{50}$ of MERS-CoV as $< 1$ TCID$_{50}$ and LD$_{50}$ as 10 TCID$_{50}$ [40]. Transgenic mice that were infected with MERS by the intranasal route presented signs of infection at a dose between 100 and 500,000 PFU ($\approx 142$ and $\approx 7.14 \times 10^5$ TCID$_{50}$) [41, 42].

3.4. Exposure route, co-infection with other respiratory viruses, and correlation with outcome

a) exposure route

SARS-CoV-2 transmission is thought to be mainly through respiratory droplets and fomites rather than through aerosols carried over long distances [43]. There are questions about whether the size of the infectious dose of COVID-19 and its route of transmission correlates with disease severity.
SARS-CoV-2 was not thought to be transmitted long distances by an aerosol in 75,465 COVID-19 patients in China [44]. A study on aerosol distribution of SARS-CoV-2 in Wuhan hospital reported the maximum distance of transmission as 4 meters in hospital wards. Reflecting this, an increased risk of positivity at sampling site and objects observed in patients’ treatment areas (40.6%) than office areas of physicians (12.5%) [45].

SARS-CoV-1 is thought to be increased by 20.4-fold when people have at least exposure for >30 minutes and distance of <1m with infected patients [46]. However, a safer physical distance to avoid transmission of SARS-CoV-2 is 1m as recommended as WHO and approximately as 2 m by CDC [47, 48]. Small droplets can, nonetheless, be found at a distance of 7-8 meter away [49]. The rate of COVID-19 transmission was increased by an estimated 18.7-fold in an enclosed area compared with the outdoor environment [50]. Transmission of SARS-CoV-2 via contaminated surfaces or aerosolization was observed in cluster analysis of COVID-19 patients [51].

During the SARS-CoV-1 outbreak in 2003 the higher risk of infection was correlated with the amount and setting of exposure [46]. in the Amoy-Garden housing complex in Hong-Kong, the lower concentrations of the virus explained the lower risk of infection in the upper floors [52]. It was estimated that the apartment’s residents were exposed to 16-160 PFU (≈ 22.8-228 TCID$_{50}$) per person depending on the floor [6].

Given the absence of direct information about SARS-CoV-2, findings from other respiratory viruses and in animals may provide clues. The potential of airborne, aerosol transmission of SARS-CoV-2 was observed in ferrets and cats [15, 53]. Aerosol inoculation with the H3N2 strain of sub-lethal influenza virus in laboratory mice, presented exacerbated mortality and morbidity, pulmonary infiltration, and inflammation, as well as 6-fold higher levels of IL-6 expression in the lungs compared to intranasally inoculated mice [54]. Consistently, African green monkeys infected by the aerosol route of SARS-CoV2 (table 2) presented with ARDS, increased level of IL6, and cytokine storms [31].

Increased exposure to the influenza virus, presumably reflecting increased infective dose, was correlated with disease progression [55]. In addition to studies of SARS-CoV-2 infected ferrets, rhesus macaques, and hamsters [16, 28, 32, 35] studies on laboratory adapted mice infected with HCoV-OC43, SARS-CoV-1and MERS reported increased morbidity and lethality with increasing dose at exposure [6, 41, 42].
b) Co-Infection

Co-infection of SARS-CoV-2 with other respiratory viruses such as non-SARS-CoV-2 Coronaviridae, rhinovirus, enterovirus, and respiratory syncytial virus are reported worldwide [56]. Most of the respiratory viruses share seasonal transmission peaks, so multiple organisms can infect people simultaneously. Although synergistic or inhibitory effects of co-infection are hypothesized given similar target cell and inflammatory pathways [57], interactions of SARS-CoV-2 with other respiratory viruses and outcome have not been quantified.

3.5. SARS-CoV-2, viral load, and outcome

COVID-19 has lower morbidity and mortality, but greater infectivity, compared with SARS and MERS [58]. The serial interval, the duration of the symptoms between the onset of symptoms in an index case and the secondary case, of COVID-19 together with viral shedding results suggest much transmission occurs early, even before onset of symptoms [59, 60]. This interval is about 3-days for influenza virus [61], 4 days for COVID-19 [59], 8.4 days for SARS-CoV-1 [62] and 14.6 days for MERS-CoV [63]. This means that infected people with SARS-CoV-2 and influenza can spread the virus faster than SARS-CoV-1 and MERS-CoV. Most COVID-19 studies show the highest viral load before or at and shortly after the onset of symptoms [60, 64-66] which may account for the rapid spreading of disease [67, 68]. The high viral load in throat swabs at or just before onset of symptoms suggests that 44% of transmission can occur in the asymptomatic stages [65].

COVID-19 and influenza share a similar pattern of viral shedding [25, 60]. There is correlation between higher viral load and the severity of COVID-19 [69, 70]. Patients with severe symptoms of COVID-19 in one study presented 60 times higher viral load and prolonged viral shedding than patients with mild symptoms [71]. In another study higher viral load was not correlated with outcomes including ICU admission, mortality, and oxygen requirement in hospitalized patients [72]. In a study on 4172 patients, higher viral loads were observed in the first phase of the outbreak and the first phase of disease. The same study reported lower viral loads in ICU patients than patients in other wards [73].

A similar viral load was observed among different age groups in one study [73] while another study found a higher viral load in children aged <5 years than adults [74]. The viral loads in
asymptomatic patients were similar to those in patients with mild to moderate COVID-19 [60]. Prolonged viral shedding, initial high viral load and increased risk of transmission in the early stage of disease was also observed in patients with seasonal coronavirus (OC43 and 229E) [75]. Patients with single seasonal coronavirus had a higher viral load than patients with co-infection [76]. Children with high viral loads of seasonal coronavirus were found to have an increased risk of symptomatic infection [75].

Studies on hamsters and African green monkeys reported no correlation between viral load and initial exposure dose of SARS-CoV-2 [31, 32] and SARS-CoV-1 [32, 77]. In contrast viral load and inoculating dose were associated in laboratory mice that were infected with SARS-CoV-1[78] respiratory syncytial virus (RSV) [79], and influenza virus [80].

During the SARS-CoV-1 outbreak at Amoy Gardens complex higher viral loads were detected in residents living in units adjacent to the index case indicating a link with exposure dose [81]. Inter-study and inter-species variability highlight that correlation of viral load and dose at exposure is not unequivocal.

4. Discussion

Effective prevention and control strategies in the pandemic of COVID-19 require understanding of infective dose, transmission, and coinfection. We found limited evidence on these points requiring us to examine the data for other relevant viruses and to combine observations on animals and humans. In humans (table 1) the infective dose varies greatly by virus and route of administration. However, for coronavirus and influenza, mostly hundreds or even more virus particles are required to cause an infection. Similarly, in animals (table 2) the infective dose varies greatly by species and by route of administration. The infective dose is generally large, with hundreds and even millions of virus particles being required to induce disease. We estimate that the infective dose for COVID-19 is probably lower than than for influenza (1000 TCID$_{50}$) as it is more contagious with a slightly higher R0. The infective dose in humans for COVID-19 was estimated as 300 particles based on computational analysis of nasopharynx in transmission and inhalation of droplets (82). The only human study on a coronavirus we found was on HCo-229E with the TCID$_{50}$ comparison was 13.
None of the animal studies reported the same clinical presentations and pathology after infection with SARS-CoV-2 as in humans. All the animals infected by aerosol and other routes of exposure presented signs of infection whereas animals exposed by the intragastric route mostly remained asymptomatic (intranasal route being intermediate). In animals, the infective dose is generally lower with aerosol transmission than other routes. The infective dose in human could be lower than currently believed if transmission by aerosol is important. Moreover, aerosol transmission can allow the virus to penetrate into the lower respiratory tract of humans and cause severe symptoms [4].

The route of infection can impact on the induction of innate and adaptive immune responses [54]. Little is known about the host immune response following different routes of infection with SARS-CoV-2. Higher viral load is not necessarily correlated with more severe symptoms, with some studies finding higher viral load in mildly symptomatic or asymptomatic stages of disease [67,72, 73]. This suggests a decline in viral load as the disease progresses [72, 73].

COVID-19 shares important features with influenza in serial interval of disease, clinical presentation, transmission route, viral load, infective dose, viral shedding, and correlation with outcome. Studies on influenza virus suggest a correlation between increasing body mass index (BMI) and increased aerosol shedding through increased frequency of small airway closure and reopening [83]. High BMI is associated with critical illness and severity of symptoms in patients with COVID-19 and influenza [84, 85].

Exhaled breath of symptomatic patients with influenza can transmit an estimated 33 particles per minute in aerosol [83]. Twenty minutes of exposure would be required for the exposure to the median infective dose of H1N1 subtype. Similarly, almost 25 particle per minute (630 particles in 25 min) in aerosol were required to cause COVID-19 infection in hACE2 mice [20]. Exposure for a similar period to SARS-CoV-2 exhaled in normal breathing of infected patients could lead to the inhaling of our estimated infective dose 300 particles of SARS-CoV-19 by aerosol, thus complementing infection by fomites and droplets. However, further studies are warranted to examine infective dose by the aerosol route and its correlation with COVID-19 severity and immune response both in animals through experiments and humans through observation.
5. Conclusion

SARS-CoV-2 has distinct features as well as commonalities compared with other similar respiratory pathogens justifying further experimental and observational studies concentrating on transmission, exposure, the infective dose, viral load, virus shedding, and the synergistic effect of viral dose and route of exposure and co-infection of SARS-CoV-2 with one or more respiratory pathogens. This review has merely laid the foundation in the study of this topic.
### Table 1: Infective dose of relevant respiratory viruses in humans

<table>
<thead>
<tr>
<th>Virus</th>
<th>Strain</th>
<th>Dose</th>
<th>Route of administration</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCID&lt;sub&gt;50&lt;/sub&gt;</td>
<td>PFU</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>a</strong> Coronavirus</td>
<td>HCoV-229E</td>
<td>13</td>
<td>9</td>
<td>NR</td>
</tr>
<tr>
<td><strong>b</strong> Influenza</td>
<td>H1N1</td>
<td>1.0×10&lt;sup&gt;3&lt;/sup&gt;</td>
<td>700</td>
<td>Intranasal</td>
</tr>
<tr>
<td></td>
<td>H2N2</td>
<td>0.6-3</td>
<td>0.42-2.1</td>
<td>Aerosol</td>
</tr>
<tr>
<td></td>
<td>H3N2</td>
<td>1.0×10&lt;sup&gt;7&lt;/sup&gt;</td>
<td>7,000,000</td>
<td>Intranasal</td>
</tr>
<tr>
<td><strong>c</strong> Rhinovirus</td>
<td>RV15</td>
<td>0.032</td>
<td>0.0224</td>
<td>Intranasal</td>
</tr>
<tr>
<td><strong>d</strong> Adenovirus</td>
<td>Type 4</td>
<td>0.5</td>
<td>0.35</td>
<td>Aerosol</td>
</tr>
<tr>
<td><strong>e</strong> Coxsackievirus</td>
<td>A21-48654</td>
<td>6</td>
<td>4.2</td>
<td>Intranasal</td>
</tr>
<tr>
<td><strong>f</strong> RSV</td>
<td>Ts-1</td>
<td>30-40 (33% infected)</td>
<td>21-28</td>
<td>Intranasal</td>
</tr>
<tr>
<td></td>
<td>Type 39</td>
<td>100</td>
<td>70</td>
<td>Aerosol</td>
</tr>
</tbody>
</table>

TCID<sub>50</sub>, %50 Tissue Infective Culture Dose; PFU, plaque-forming units; tgMice, Transgenic Mice; RSV, Respiratory Syncytial Virus; MERS, Middle East Respiratory Syndrome; NR, not reported.
Table 2: Experimental studies on the infective dose of coronaviruses in various mammals

<table>
<thead>
<tr>
<th>Virus</th>
<th>Host</th>
<th>Dose (PFU)</th>
<th>Route of inoculation</th>
<th>Numbers and/or %, signs of infection</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>a Ferret</td>
<td>221,359</td>
<td>IN</td>
<td>6/6</td>
<td>Kim et al. [15]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>500</td>
<td>IN</td>
<td>16.7,1/6</td>
<td>Ryan et al. [16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50,000</td>
<td>IN</td>
<td>6/6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>420,000</td>
<td>IN</td>
<td>4/4</td>
<td>Richard et al. [17]</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>b hACE2 mice</td>
<td>70,000</td>
<td>IN</td>
<td>36.8,7/19</td>
<td>Bao et al. [18]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>400,000</td>
<td>IN</td>
<td>3/3</td>
<td>Sun et al. [19]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,000,000</td>
<td>IG</td>
<td>1/3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>630</td>
<td>Aerosol</td>
<td>2/2</td>
<td>Bao et al. [20]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21000</td>
<td>IN</td>
<td>50% Lethal</td>
<td>Jiang et al. [21]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100,000</td>
<td>IN</td>
<td>40% Lethal</td>
<td>Dinnon et al. [22]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16,000</td>
<td>IN</td>
<td>3/3</td>
<td>Gu et al. [23]</td>
</tr>
<tr>
<td>HCoV-OC43</td>
<td>BALB/c &amp; C57B6 mice</td>
<td>70,000</td>
<td>IP/IC</td>
<td>100% Lethal</td>
<td>Jacomy et al. [38]</td>
</tr>
<tr>
<td></td>
<td>BALB/c mice</td>
<td>70</td>
<td>IC</td>
<td>100% Lethal</td>
<td>Shen et al. [39]</td>
</tr>
<tr>
<td>SARS-CoV-1</td>
<td>tgMice</td>
<td>280</td>
<td>IN</td>
<td>NR</td>
<td>Watanabe et al. [6]</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>tgMice</td>
<td>0.7</td>
<td>IN</td>
<td>NR</td>
<td>Tao et al. [40]</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>c Cynomolgus macaques</td>
<td>48,600</td>
<td>Aerosol</td>
<td>4/4</td>
<td>Johnston et al. [24]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>700,000</td>
<td>IN/IT</td>
<td>4/4</td>
<td>Rockx et al. [25]</td>
</tr>
</tbody>
</table>
**Table 2: Continued**

<table>
<thead>
<tr>
<th>Virus</th>
<th>Host</th>
<th>Dose (PFU)</th>
<th>Route of inoculation</th>
<th>Numbers and/or %, signs of infection</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>d Rhesus macaques</td>
<td>700,000</td>
<td>IO</td>
<td>2/2</td>
<td>Deng et al. [26]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IT</td>
<td>1/1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IG</td>
<td>0/2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,820,000</td>
<td>IN/IT/IO/Oral</td>
<td>8/8</td>
<td>Munster et al. [27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11,000</td>
<td>IN/IT</td>
<td>3/3</td>
<td>Chandrashekar et al. [28]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>110,000</td>
<td>IN</td>
<td>3/3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,100,000</td>
<td>IN</td>
<td>3/3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>28700</td>
<td>Aerosol</td>
<td>4/4</td>
<td>Johanston et al. [24]</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>e African green monkeys</td>
<td>38000</td>
<td>Aerosol</td>
<td>3/3</td>
<td>Johanston et al. [24]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>500,000</td>
<td>IN/IT</td>
<td>6/6</td>
<td>Woolsey et al. [29]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,000,000</td>
<td>IN</td>
<td>6/6</td>
<td>Cross et al. [30]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2000</td>
<td>Aerosol</td>
<td>2/2</td>
<td>Blair et al. [31]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,610,000</td>
<td>IO/IT/IN/Oral</td>
<td>2/2</td>
<td></td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>f Syrian hamster</td>
<td>398,107</td>
<td>IN/IO</td>
<td>4/4</td>
<td>Imai et al. [32]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000</td>
<td></td>
<td>4/4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>56000</td>
<td>IN</td>
<td>3/3</td>
<td>Sia et al. [33]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100,000</td>
<td>IN</td>
<td>75,24/36</td>
<td>Osterrieder et al. [34]</td>
</tr>
<tr>
<td>Immunocompromised Syrian hamster</td>
<td></td>
<td>100</td>
<td>IN</td>
<td>10/10</td>
<td>Brocato et al. [35]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10,000</td>
<td></td>
<td>40%Lethal</td>
<td></td>
</tr>
<tr>
<td>Bats</td>
<td></td>
<td>70,000</td>
<td>IN</td>
<td>78,7/9</td>
<td>Schlottau et al. [36]</td>
</tr>
</tbody>
</table>

TCID<sub>50</sub>, %50 Tissue Infective Culture Dose; PFU, plaque-forming units; tgMice, Transgenic Mice; hACE2, human angiotensin converting enzyme 2, BALB/c; begg albino laboratory-bred mouse, IN; intranasal, IG; intragastric, IO; intraocular, IT; intrathecal, IC; intracerebral, IP; intraperitoneal, NR; not reported


